Targeted drug combo offers hope for Tough-to-Treat leukemia
NCT ID NCT01371630
Summary
This study is testing a combination of a targeted cancer drug (inotuzumab ozogamicin), low-intensity chemotherapy, and an immunotherapy drug (blinatumomab) for adults with acute lymphoblastic leukemia (ALL). It focuses on older patients (60+) or younger patients who are too frail for standard high-dose chemotherapy, as well as those whose cancer has returned or resisted prior treatment. The main goals are to find the safest dose and see how well this approach controls the leukemia and extends survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.